Results

1–10 of 19 results for Neovascular AMD Clinical trials

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019
Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2019
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
2019
Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2019
Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy
Michael W. Stewart, MD
Annual Meeting Talks
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019
Higher-Order Optical Coherence Tomography Fluid Burden Assessment: Analysis From the OSPREY Trial
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2019
What Do the HARBOR Data Reveal About the Relationship Between the Drying of Subretinal and Intraretinal Fluid and Associated Vision Outcomes?
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2019
Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials
Carl D. Regillo, MD
Annual Meeting Talks
2019